The San Diego based-company earned 9 cents a share, excluding charges, compared to 13 cents a share in the year-ago period, meeting the
First Call/Thomson Financial
consensus estimate of 10 analysts.
Dura also reported net losses, including nonrecurring charges, of $98.7 million, or $2.20 a share, for the third quarter. Pharmaceutical sales in the third quarter rose 7% to $58 million from $54.2 million, while total revenue fell to $70.1 million, from $71.6 million a year earlier.